Cargando…
RNAi therapeutics: a potential new class of pharmaceutical drugs
The rapid identification of highly specific and potent drug candidates continues to be a substantial challenge with traditional pharmaceutical approaches. Moreover, many targets have proven to be intractable to traditional small-molecule and protein approaches. Therapeutics based on RNA interference...
Autores principales: | Bumcrot, David, Manoharan, Muthiah, Koteliansky, Victor, Sah, Dinah W Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097247/ https://www.ncbi.nlm.nih.gov/pubmed/17108989 http://dx.doi.org/10.1038/nchembio839 |
Ejemplares similares
-
A status report on RNAi therapeutics
por: Vaishnaw, Akshay K, et al.
Publicado: (2010) -
Tissue-specific gene silencing monitored in circulating RNA
por: Sehgal, Alfica, et al.
Publicado: (2014) -
Acyclic (S)-glycol nucleic acid (S-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency
por: Egli, Martin, et al.
Publicado: (2023) -
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
por: Butler, James S., et al.
Publicado: (2016) -
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
por: Novobrantseva, Tatiana I, et al.
Publicado: (2012)